BOND-002
29 evidence topics · 7 sources
Objective
Location and study date
Registered study dates and sites
| Field | Quoted record |
|---|---|
| Study start (actual) | “2015-06-02” |
| Primary completion (actual) | “2018-08” |
| Study completion (actual) | “2019-02” |
| Number of sites | “This study has 17 locations” |
| Principal investigator | “Gary Steinberg, MD” |
Study design
Registered design: open-label, single-arm, phase 2
Registered design details
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Company description of the design and population
Eligibility criteria
Inclusion: high-grade NMIBC after prior intravesical therapy including BCG
Inclusion: carcinoma in situ, or recurrent Ta or T1 disease
Inclusion: cystectomy declined, age, and performance status
Prior therapy of the interim population
“All patients received at least 2 prior courses of intravesical therapy for CIS, with at least 1 being a course of BCG.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients had either failed BCG induction therapy within 6 months or had been successfully treated with BCG with subsequent recurrence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Registered regimen
Company description of dose, induction, and maintenance
Study outcomes
Rationale for using durable complete response at 18 months as the primary endpoint
Registered primary endpoint: durable complete response proportion
Endpoint reported in the interim analysis: complete response at 6 months
Regulatory context for durable complete response in single-arm trials
Statistical analysis description
Number of participants (Planned and analyzed)
Registered enrollment
| Field | Quoted record |
|---|---|
| Enrollment (actual) | “66” |
Description of analysis sets
Interim efficacy set: participants with 6-month follow-up
Safety set: protocol participants and three additional treated patients
Results
Participant disposition
No evidence found.
Baseline characteristics
Tumor stage at entry in the interim population
Efficacy results
Complete response at 6 months: interim analysis
“Overall 6-month CR (95% CI) was 47% (32%-62%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Considering 6-month CR for pathologic subsets, pure CIS was 58% (37%-78%), CIS ± Ta/T1 50% (33%-67%), and pure Ta/T1 33% (8%-70%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 6 months, the single patient that progressed to muscle-invasive disease had Ta and T1 tumors at baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“No patients with pure T1 had 6-month CR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Complete response at any time and duration of response: company report
Complete response at 6 and 12 months in CIS-containing disease: company report
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events at 6 months: interim analysis
“Treatment-related adverse events (AEs) at 6 months were most commonly urinary bladder spasms (36%), hematuria (28%), dysuria (25%), and urgency (22%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Immunologic treatment-related AEs included flu-like symptoms (12%) and fatigue (6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Grade III treatment-related AEs included dysuria (3%) and hypotension (1.5%). There were no Grade IV/V treatment-related AEs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related and serious adverse events: company report
Study limitations
Summary: limitations of BOND-002
- Design: BOND-002 was a phase 2, open-label, single-arm study with no comparator arm.
- Population: the 10-K describes the enrolled population as “a heterogenous mixture of BCG-exposed and BCG-unresponsive NMIBC”. Eligibility allowed participants whose second BCG course had as few as two weekly treatments, and 19 of the 65 enrolled participants had Ta/T1 disease alongside 46 with CIS, so the population differs from the BCG-unresponsive population of BOND-003.
- Endpoint reporting: the registered primary endpoint is durable complete response lasting 12 months or longer and assessed at 18 months. The only peer-reviewed report is an interim analysis of 45 participants that reported complete response at 6 months (47%). The final figures (40 of 65 participants, 61.5%, with complete response at any time; 30 of 46 participants, 65.2%, with CIS-containing disease) come from company filings, and no peer-reviewed report of the registered primary endpoint was identified.
- Enrollment counts differ by source: the registry lists 66 participants enrolled, and the 10-K reports 65 enrolled per protocol, with 3 additional treated participants in the safety set.
- Regimen: maintenance in BOND-002 was six weekly instillations at months 6, 12, and 18, a schedule that differs from the one used in BOND-003.
- No results posted on ClinicalTrials.gov were identified.